Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | PPM1B | O75688 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | TLR4 | O00206 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5699527 | 1.00 | ALDH1A1 (0.37) | ALDH1A1PPM1BPTPN1PPP1CCCYP4F2 | |
| SCHEMBL6527016 | 0.83 | ALDH1A1 (0.39) | ALDH1A1MAPTTSHRKMT2AKDM4E | |
| SCHEMBL5186955 | 0.76 | ALDH1A1 (0.38) | ALDH1A1PPM1BPTPN1PPP1CCCYP4F2 | |
| SCHEMBL12966496 | 0.74 | — | — | |
| SCHEMBL3039889 | 0.74 | — | — | |
| SCHEMBL563498 | 0.74 | — | — | |
| SCHEMBL472111 | 0.72 | ALDH1A1 (0.41) | ALDH1A1PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL817452 | 0.72 | ALDH1A1 (0.41) | ALDH1A1PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL12559863 | 0.72 | ALDH1A1 (0.41) | ALDH1A1PPM1BPTPN1PPP1CCMAPT | |
| SCHEMBL11311453 | 0.72 | ALDH1A1 (0.41) | ALDH1A1PPM1BPTPN1PPP1CCMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136591-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| CN-119630670-A | Modulators of TNFalpha activity and uses thereof | 瑞雷拉公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20250082614-A1 | METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | CYTEIR THERAPEUTICS, INC. | 2025-03-13 | — | — | US | disclosed |
| CN-114514023-B | Methods of treating pancreatic cancer using RAD51 inhibitors | 赛泰尔治疗公司 | 2025-01-14 | — | — | CN | disclosed |
| US-12064419-B2 | Methods of using RAD51 inhibitors for treatment of pancreatic cancer | CYTEIR THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| CN-111542521-B | RAD51 inhibitors | 赛泰尔治疗公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-4112616-A1 | RAD51 INHIBITORS | Cyteir Therapeutics, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-3681884-B1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS INC (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-3681884-B1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS INC (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-3986402-A1 | METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | Cyteir Therapeutics, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-10336746-B1 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336746-B1 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190194182-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190194182-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190077799-A1 | RAD51 Inhibitors | CYTEIR THERAPEUTICS, INC. | 2019-03-14 | — | — | US | disclosed |
| WO-2019051465-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| WO-2019051465-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| US-20190077799-A1 | RAD51 Inhibitors | CYTEIR THERAPEUTICS, INC. | 2019-03-14 | — | — | US | disclosed |
| EP-1341927-B1 | METHOD OF PREPARING 3-¬2-{(METHYLSULFONYL)OXY}ETHOXY|-4-(TRIPHENYLMETHOXY)-1-BUTANOL, METHANE SULFONATE | PPG IND OHIO INC (US) | 2006-08-02 | — | — | EP | disclosed |
| US-6300106-B1 | FORMING S-ISOMER OR R-ISOMER OF (3,6-DIHYDRO-2H-PYRAN-2-YL)-METHANOL VIA A PROCESS WHICH PRODUCES A RACEMIC MIXTURE OF INTERMEDIATE REACTION PRODUCTS, RESOLVING TO SELECTIVELY PRODUCE S ISOMER | PPG INDUSTRIES OHIO, INC. | 2001-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336746-B1 | RAD51 inhibitors | RAD51, MRE11, RAD54L | ALDH1A1 4493/4885PPM1B 1396/4885PTPN1 3902/4885 |
| US-20250082614-A1 | METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | RAD51, MRE11, RAD52 | ALDH1A1 4466/4885PPM1B 1344/4885PTPN1 3875/4885 |
| US-20250136591-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | ALDH1A1 4493/4885PPM1B 1396/4885PTPN1 3902/4885 |
| US-20190194182-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | ALDH1A1 4493/4885PPM1B 1396/4885PTPN1 3902/4885 |
| US-12064419-B2 | Methods of using RAD51 inhibitors for treatment of pancreatic cancer | RAD51, MRE11, RAD52 | ALDH1A1 4466/4885PPM1B 1344/4885PTPN1 3875/4885 |
| US-20190077799-A1 | RAD51 Inhibitors | RAD51, MRE11, RAD54L | ALDH1A1 4493/4885PPM1B 1396/4885PTPN1 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.